Koi Biotherapeutics has developed the CAR-Enhancer platform, which utilizes a protein-driven mechanism to enhance the persistence of CAR T-cells in blood cancer therapies. This approach aims to generate memory CAR cells, improving treatment efficacy and reducing the risk of relapse for patients with conditions such as Multiple Myeloma, Lymphomas, and Leukemia.
Funding
Funding not disclosed
Founders
Product
Problem
CAR T-cell therapies for blood cancers like multiple myeloma, lymphomas, and leukemia often suffer from limited persistence, leading to compromised efficacy, primary resistance, and increased risk of relapse. The challenge lies in enhancing the longevity and sustained activity of CAR T-cells within the patient.
Solution
Koi Biotherapeutics is developing the CAR-Enhancer platform, a protein-driven mechanism designed to improve the persistence of CAR T-cells without requiring specific engineering steps on the CAR T-cells themselves. This approach aims to drive CAR T-cells toward the generation of memory CAR cells, potentially leading to more durable and curative therapies. The CAR-Enhancer platform is designed to be universally compatible with all CAR T-cells, expanding its therapeutic applicability. Preclinical results suggest the platform has the potential to significantly improve CAR T-cell therapy outcomes.
Target Audience
The primary target audience includes patients with blood cancers such as multiple myeloma, lymphomas, and leukemia, as well as the clinicians and healthcare providers who treat them with CAR T-cell therapies.
Features
- Protein-driven mechanism to enhance CAR T-cell persistence
- Promotes the generation of memory CAR T-cells
- Universal compatibility with all CAR T-cell therapies
- No genetic engineering of CAR T-cells required